Morgan Stanley Reiterates Equal-Weight on Blueprint Medicines, Maintains $55 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz has reiterated an Equal-Weight rating on Blueprint Medicines (NASDAQ:BPMC) and maintained a $55 price target.
July 14, 2023 | 2:50 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has reiterated an Equal-Weight rating on Blueprint Medicines and maintained a $55 price target.
The reiteration of the Equal-Weight rating and the maintenance of the $55 price target by Morgan Stanley indicates that the analyst sees the stock as fairly valued at current levels. This could potentially limit any significant short-term price movement.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100